In a report released yesterday, Maury Raycroft from Jefferies reiterated a Buy rating on Immune Design (NASDAQ: IMDZ), with a price target of $7. The company’s shares closed yesterday at $3.60, close to its 52-week low of $2.80.
According to TipRanks.com, Raycroft is a 5-star analyst with an average return of 29.9% and a 58.3% success rate. Raycroft covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Atara Biotherapeutics, and Intellia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immune Design with a $7 average price target, which is a 94.4% upside from current levels. In a report released yesterday, Cowen & Co. also maintained a Buy rating on the stock.
.
See today’s analyst top recommended stocks >>
Based on Immune Design’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $13.81 million. In comparison, last year the company had a GAAP net loss of $13.85 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Seattle, WA.
